When combined, 6 common, recognized radiotherapy safety checks cut potential patient-harming errors by 90%, according to a new study led by Johns Hopkins researchers.
BOSTON—The national discourse on cancer screening has come a long way since 1988, when Ronald Reagan became the first president to say “breast cancer” in public, noted Alec Stone, MA, MPA, Health Policy Director, Oncology Nursing Society (ONS). In 2009, after the US Preventive Services Task Force (USPSTF) recommended mammography screening every 2 years instead of annually, beginning at 50 years of age instead of 40, the public outcry was widespread and loud. Controversy has also been swirling about prostate cancer screening recommendations.
Extravasation is always a risk when administering medicines intravenously. This is when the infused drug infiltrates the tissue surrounding the injection site. The resulting injury can range from mild to lifethreatening, depending on whether the drug involved is classified as an irritant or a vesicant.
The Infusion Nurses Society (INS) defines a vesicant as “an agent capable of causing injury when it escapes from the intended vascular pathway into the surrounding tissue.”1
SAN ANTONIO—Researchers are reporting “woefully inadequate” mammography rates in American women, even in those with healthcare coverage.
Milayna Subar, MD, National Practice Leader, Medco Oncology Therapeutic Resource Center in Franklin Lakes, New Jersey, and colleagues analyzed medical claims data obtained in more than 1.5 million women between 2006 and 2009. All of the women had health insurance through their employer or Medicare.
CHICAGO—“Dasatinib 100 mg once daily should become frontline therapy in newly diagnosed chronic-phase chronic myelogenous leukemia,” said DASISION (Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients; CA180-056) lead investigator Hagop M. Kantarjian, MD, The University of Texas, M. D. Anderson Cancer Center, Houston. Kantarjian’s statement was based on findings from the DASISION comparison of firstline dasatinib with first-line imatinib in patients with chronic-phase chronic myelogenous leukemia (CP-CML).
Results 1 - 10 of 11